Metformina Generis

Metformin, the active ingredient in Metformina Generis, is a Biguanide presented as a unknown strength/oral dosage form for oral use. It treats type 2 diabetes mellitus in adult patients by improving insulin sensitivity and reducing hepatic glucose output.

GNH USA supplies Metformina Generis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina Generis, a Biguanide, is employed in the management of disorders related to insulin resistance and hyperglycaemia. - Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial blood glucose. - Prediabetes: helps delay progression to overt diabetes by enhancing insulin sensitivity. - Polycystic ovary syndrome (PCOS): reduces insulin resistance and may improve menstrual regularity.

Metformina Generis may be associated with a range of adverse reactions.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or indigestion. - Diarrhoea: loose stools, often transient. - Metallic taste: altered taste perception. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycaemia: usually when combined with other glucose‑lowering agents. - Vitamin B12 deficiency: may develop with long‑term use. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Allergic skin reactions: rash, urticaria, or Stevens‑Johnson syndrome. - Pancreatitis: inflammation of the pancreas.

Before initiating Metformina Generis, several safety considerations should be reviewed. - Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Liver disease: contraindicated in patients with significant hepatic dysfunction. - Cardiac failure: use with caution in congestive heart failure. - Alcohol consumption: limit intake as it may increase risk of lactic acidosis. - Vitamin B12 monitoring: periodic assessment recommended for long‑term therapy. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformina Generis can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal dysfunction. - Cimetidine: can increase metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis. - Nucleoside reverse transcriptase inhibitors: may raise metformin exposure. - Loop or thiazide diuretics: can affect renal clearance of metformin.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycaemia. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Sulfonylureas: increased risk of hypoglycaemia when combined. - Corticosteroids: may reduce glucose‑lowering efficacy. - Thyroid hormones: may alter glycaemic control requiring dose adjustment.